Investor Relations

Today, Ambu announces preliminary Q1 2024/25 results and raises expectations for the full 2024/25 financial year. The outlook for organic revenue growth is set to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%).

The raised organic growth outlook is mainly driven by better-than-expected revenue growth in Anaesthesia & Patient Monitoring, driven by price increases and solid volume growth. In addition, the raised outlook is supported by continued strong organic growth in Endoscopy Solutions, driven by solid pulmonology momentum and continued strong growth across urology, ear-nose-throat (ENT) and gastroenterology (GI).

Furthermore, the raised EBIT margin outlook is driven by continued strengthened operational leverage in OPEX from organic revenue growth and is also positively affected by the strengthening of the USD/DKK currency, relative to the previous outlook from 5 November 2024. Finally, the updated EBIT guidance reflects the increased expectations for organic revenue growth and also includes an expectation of continued investments to support growth for the remainder of the financial year.

PRELIMINARY AND UNAUDITED FINANCIAL HIGHLIGHTS FOR Q1 2024/25
Last year’s comparative figures are stated in brackets.

• Revenue was DKK 1,510m (DKK 1,254m), with organic revenue growth of 19.5% (14.2%), mainly driven by continued strong growth in both pulmonology and urology, ENT and GI within Endoscopy Solutions, delivering a combined total growth of 20.6% (25.1%), supplemented by strong growth of 17.8% (1.2%) in Anaesthesia & Patient Monitoring, driven by price increases and solid volume growth, combined with a weaker comparison quarter. Total reported growth for the quarter was 20.4% (10.9%).
• EBIT before special items was DKK 243m (DKK 126m), with an EBIT margin before special items of 16.1% (10.0%). The strengthened EBIT margin was primarily driven by operational leverage on OPEX from organic growth, as well as the continued strengthening of the USD/DKK currency, although partially offset by increased investments aimed at driving organic growth.
   

REVISED OUTLOOK FOR THE FISCAL YEAR 2024/25
Driven by the development in the first quarter of the 2024/25 financial year, Ambu’s 2024/25 financial outlook is set as per below:

In addition, Ambu now expects the organic revenue growth for Anaesthesia & Patient Monitoring to reach mid-to-high single digits (previously mid-single digits).

Ambu’s expectations for the Endoscopy Solutions organic revenue growth are unchanged at +15%. Similarly, Ambu’s free cash flow expectations are maintained at DKK +500m.

Ambu will publish its full Q1 2024/25 interim results, as previously announced, on 30 January 2025.
 

Download and read the full company announcement here.

With the launch of the Ambu^® SureSight™ Connect solution, Ambu offers clinicians the only airway visualisation and pulmonology offering that features a one-lung ventilation solution and includes all the devices recommended for intubation and airway assessment.

Today, Ambu announces the launch of its new video laryngoscopy solution, Ambu^® SureSight™ Connect, in full integration with Ambu’s advanced digital software systems, Ambu^® aView™ 2 Advance and Ambu^® aBox™ 2.

This new solution is designed to facilitate efficient intubation in both routine and difficult airway procedures in the operating room (OR) and intensive care unit (ICU). Endotracheal intubation is one of the most common airway management procedures, with over 15 million intubations performed annually in the USA alone.

The Ambu^® SureSight™ Connect expands Ambu’s comprehensive airway visualization and pulmonology offering, making it the only offering that features a one-lung ventilation solution and includes all the devices recommended for intubation and airway assessment.¹

"From the introduction of the first self-inflating resuscitation breathing bags in 1956, to the upcoming integration of state-of-the-art video laryngoscopy into a versatile airway visualization and pulmonology offering, Ambu is the anesthesiologist’s partner in providing the best care. I have worked with Ambu for more than 15 years and have found it to hold the highest standards in the development of airway tools and in teaching the clinician to appropriately apply them. Ambu seeks the input of clinicians, such as myself, in the development of devices that serve our patients and constantly strives for improvement."

DR. WILLIAM H. ROSENBLATT²
Professor at Yale University School of Medicine, USA

In addition to the new video laryngoscope, Ambu’s airway visualization and pulmonology offering includes the company’s range of single-use bronchoscopes, rhinolaryngoscopes as well as single- and double-lumen tubes with an integrated camera for one-lung ventilation procedures³ – all in integration with Ambu’s digital software systems. Ambu’s integrated airway visualization and pulmonology offering allows clinicians to switch between solutions as needed. This reduces task complexity and simplifies workflow efficiency in a cluttered workspace, giving clinicians more time to focus on patients, while maintaining high standards of patient safety.

Furthermore, the advanced data management capabilities of Ambu’s digital software systems enable clinicians to streamline the sharing of patient imaging data with hospitals’ IT systems.

Starting January 2025, Ambu will initiate the launch of the Ambu^® SureSight™ Connect solution in the USA, followed by launches in additional markets throughout 2025. Initially, Ambu will engage in a so-called controlled market release phase, collaborating with healthcare professionals at key hospitals to evaluate the solution’s performance in clinical settings before engaging in a full commercial launch later in the financial year.

"With our new video laryngoscopy solution, we are significantly extending our airway visualization and pulmonology offering to our customers. This important advancement allows us to meet their needs with the most comprehensive portfolio in the industry, ensuring they can work more efficiently to deliver the highest standards of patient care. Furthermore, it solidifies Ambu’s strong leadership position in airway management and pulmonology, showcasing our continued commitment to customer-centric innovation."

BRITT MEELBY JENSEN
Chief Executive Officer, Ambu

Read and download the full press release here

Today, 4 December 2024, Ambu A/S held its annual general meeting, at which the following items were adopted: 

Approval of the Company’s annual report and consolidated financial statements  
The presented audited annual report for the financial year 2023/24 was adopted by the shareholders. 

Approval of the remuneration report  
The proposed and presented remuneration report for the financial year 2023/24 was adopted by the shareholders. 

Approval of the appropriation of profit in accordance with the adopted annual report  
The Ambu Group reported a net profit for the year of DKK 235 million. 

The Board of Directors proposed a dividend of DKK 0.38 per share of nominally DKK 0.50 so that a dividend in the total amount of DKK 102 million be paid out of the net profit for the year, corresponding to 43% of the Group’s net profit, whereas the remaining part of the net profit be carried forward to next year. 

Approval of the Board of Directors' remuneration for the financial year 2024/25  
The Board of Directors proposed that the remuneration of the Board of Directors, which was most recently adjusted for the financial year 2020/21, be increased for the current financial year (2024/25) as follows: 

• Ordinary members of the Board of Directors receive basic remuneration amounting to DKK 400,000. 
• The Chair receives three times the basic remuneration (DKK 1,200,000). 
• The Vice Chair receives twice the basic remuneration (DKK 800,000). 
• In addition, each member of a Board committee receives remuneration of DKK 132,000 per committee seat, however, the Chair of a Board committee receives remuneration of DKK 200,000 per chairmanship.

​Election of Chair of the Board of Directors   
Jørgen Jensen was re-elected as chair of the Board of Directors. 

Election of Vice Chair of the Board of Directors  
Shacey Petrovic was re-elected as vice Chair of the Board of Directors. 

Election of other members of the Board of Directors  
Michael del Prado, Susanne Larsson and Simon Hesse Hoffmann were re-elected as members of the Board of Directors.  

Furthermore, David Hale was elected as a new member of the Board of Directors.

Election of auditor  
EY Godkendt Revisionspartnerselskab was appointed as the Company’s auditor in respect of statutory financial reporting as well as assurance engagements relating to sustainability reporting.  

Authorisation to the Chair of the meeting      
The Chair of the meeting was, with full right of substitution, authorised to apply for registration of the resolutions passed and to make any such amendments thereto as the Danish Business Authority or other authorities may require or request as a condition for registration or approval, as well as to continuously make and apply for registration of linguistic and other non-substantive adjustments to the company’s Articles of Association. 
 

--------------------- 
 

Meeting adjourned.


Read and download the full company announcement here